Has Carolyn Aks, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,638 in general payments to Carolyn Aks, MD across 419 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Carolyn Aks, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Carolyn Aks, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Carolyn Aks, MD

Hematology & Oncology · Havre, MTNPI 1518905678

Payments from drug & device makers

$8,638in general payments, 2019–2025

Across 419 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$889
Genentech USA, Inc.$671
Novartis$634
E.r. Squibb & Sons, L.L.C.$599
Johnson & Johnson$577
Astellas Pharma US Inc$515
plus $5K from 51 others

What the payments were for

Speaking & faculty fees$1021%
Food & beverage$7,73290%
Education$8039%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	34	$889
Genentech USA, Inc.	35	$671
Novartis	34	$634
E.r. Squibb & Sons, L.L.C.	27	$599
Johnson & Johnson(2 entities)	25	$577
Astellas Pharma US Inc	19	$515
Merck	20	$482
Takeda Pharmaceuticals U.S.A., Inc.	18	$444
AstraZeneca	17	$387
Pfizer	33	$292
Bristol Myers Squibb	15	$262
Sanofi	9	$257
Seagen Inc.	9	$207
Bayer	10	$204
Lilly USA, LLC	9	$145
Eisai Inc.	8	$145
Medtronic	1	$125
Rigel Pharmaceuticals, Inc.	6	$118
AbbVie	6	$112
Foundation Medicine, Inc.	1	$102
Pharmacyclics LLC, An Abbvie Company	5	$102
Incyte Corporation	6	$95
AVEO Pharmaceuticals, Inc.	2	$90
Taiho Oncology, Inc.	4	$70
Boehringer Ingelheim	4	$66
Agios Pharmaceuticals, Inc.	4	$63
Clovis Oncology, Inc.	4	$61
Tesaro, Inc.	3	$60
Sirtex Medical Inc	4	$60
Sanofi-aventis U.S. LLC	3	$58
Sun Pharmaceutical Industries Inc.	2	$52
EMD Serono, Inc.	3	$51
Regeneron Healthcare Solutions, Inc.	3	$49
Gilead	3	$47
GSK	3	$43
Daiichi Sankyo Inc.	2	$41
Dova Pharmaceuticals	2	$37
Helsinn Therapeutics (U.S.), Inc.	2	$36
Sumitomo Pharma America, Inc.	2	$33
Beigene USA, Inc.	2	$30
Kyowa Kirin, Inc.	2	$29
Janssen Scientific Affairs, LLC	2	$27
Jazz Pharmaceuticals Inc.	2	$26
Myriad Genetic Laboratories, Inc.	1	$23
Epizyme, Inc.	1	$20
Secura Bio, Inc.	1	$20
Acrotech Biopharma Inc.	1	$20
Exelixis Inc.	1	$19
Ipsen Biopharmaceuticals, Inc	1	$19
EUSA Pharma (US) LLC	1	$19
Aurobindo Pharma USA, Inc.	1	$19
Acceleron Pharma, Inc.	1	$17
Array Biopharma Inc	1	$17
Tersera Therapeutics LLC	1	$15
Immunomedics, Inc.	1	$14
Puma Biotechnology, Inc.	1	$12
Blueprint Medicines Corporation	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,638 in reported general payments places this provider in the 55th percentile of 37 hematology & oncology providers in Montana.

See all hematology & oncology providers in Montana →

Medicare billing

Part B allowed, 2024

$740,020

Medicare patients

112

Services billed

32,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Exemestane	11	$782
Tamoxifen Citrate	22	$431
Prochlorperazine Maleate	16	$244
Dexamethasone	13	$205
Ondansetron Hcl	19	$123
Pantoprazole Sodium	18	$108
Oxycodone Hcl	11	$89
Acyclovir	11	$78
Gabapentin	16	$70

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Havre

Patrick CobbBillings$14.7M
Grant HarrerGreat Falls$236K
Dhimant PatelBozeman$233K
Karl GuterGreat Falls$200K
Elise AnderesKalispell$140K
Mark HancockBozeman$97K
Benjamin MarchelloBillings$68K
Patrick TangGreat Falls$62K
William ConkrightBozeman$54K
Michael KiddBillings$33K

See the full list for Montana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →